Alligator Bioscience AB (SE:ATORX)
:ATORX
Top Page
Alligator Bioscience AB
(ATORX)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr0.17
â–¼(-49.41% Downside)
Action:ReiteratedDate:04/11/26
The score is held down primarily by very weak financial performance (persistent losses, sharply lower revenue, heavy and worsening cash burn, and weakened balance sheet/leverage risk). Technicals add modest downside/neutral pressure given a longer-term downtrend and negative MACD, while valuation provides limited support due to negative earnings and no dividend yield data.
Positive Factors
Focused immuno-oncology pipeline
A concentrated scientific focus on tumor-directed immunotherapies and antibody modalities aligns the company with a large, durable oncology market and long-term industry R&D trends. Specialization increases chances of technical differentiation, clearer clinical development paths, and attractive partnering interest from larger biopharma over multi-year horizons.
Negative Factors
Severe cash burn and weak cash generation
Sustained, deep negative operating and free cash flows and a surge in 2025 cash burn create a structural reliance on external financing. Over a multi-month horizon this raises dilution and refinancing risk, constrains R&D pacing and partnering leverage, and can force unfavorable deal terms or program delays if funding access tightens.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused immuno-oncology pipeline
A concentrated scientific focus on tumor-directed immunotherapies and antibody modalities aligns the company with a large, durable oncology market and long-term industry R&D trends. Specialization increases chances of technical differentiation, clearer clinical development paths, and attractive partnering interest from larger biopharma over multi-year horizons.
Read all positive factors
Alligator Bioscience AB (ATORX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr96.32M
Dividend YieldN/A
Average Volume (3M)1.75M
Price to Earnings (P/E)―
Beta (1Y)0.69
Revenue Growth52.38%
EPS Growth74.36%
CountrySE
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.66
Shares Outstanding534,516,970
10 Day Avg. Volume1,169,449
30 Day Avg. Volume1,745,933
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.35
Price to Sales (P/S)18.04
P/FCF Ratio-0.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)kr11.90M
Alligator Bioscience AB Business Overview & Revenue Model
Company Description
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary hu...
How the Company Makes Money
Alligator Bioscience makes money primarily through its drug development and partnering model rather than product sales. Key revenue sources typically include: (1) Collaboration and licensing income: upfront payments received when the company out-l...
Alligator Bioscience AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 514.00K | 57.77M | 58.11M | 35.70M | 12.94M |
| Gross Profit | -110.03M | 57.77M | 58.11M | -112.03M | -74.04M |
| EBITDA | -121.98M | -165.47M | -237.61M | -180.99M | -130.39M |
| Net Income | -51.35M | -233.89M | -248.59M | -193.40M | -141.74M |
Balance Sheet | |||||
| Total Assets | 110.60M | 104.34M | 118.45M | 169.58M | 333.20M |
| Cash, Cash Equivalents and Short-Term Investments | 62.20M | 64.31M | 66.12M | 97.31M | 278.15M |
| Total Debt | 43.15M | 43.57M | 16.10M | 24.50M | 9.74M |
| Total Liabilities | 103.74M | 234.93M | 106.59M | 80.53M | 50.93M |
| Stockholders Equity | 6.86M | -130.59M | 11.86M | 89.05M | 282.27M |
Cash Flow | |||||
| Free Cash Flow | -157.45M | -212.43M | -191.74M | -173.05M | -127.08M |
| Operating Cash Flow | -155.99M | -212.43M | -189.28M | -172.61M | -127.03M |
| Investing Cash Flow | 2.21M | 0.00 | -2.46M | -440.00K | -45.00K |
| Financing Cash Flow | 152.59M | 211.27M | 161.56M | -7.83M | 301.80M |
Alligator Bioscience AB Technical Analysis
Neutral
0.34
Price Trends
0.18
Negative
0.24
Negative
0.74
Negative
Market Momentum
>-0.01
Negative
49.75
Neutral
30.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ATORX, the sentiment is Neutral. The current price of 0.34 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.18, and below the 200-day MA of 0.74, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.75 is Neutral, neither overbought nor oversold. The STOCH value of 30.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ATORX.
Alligator Bioscience AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr160.80M | -1.70 | -1291.15% | ― | ― | 28.54% | |
44 Neutral | kr153.50M | -1.48 | -52.45% | ― | 2.56% | 52.76% | |
43 Neutral | kr91.43M | -3.17 | -21.31% | ― | -67.00% | 13.62% | |
43 Neutral | kr41.11M | -1.03 | -457.91% | ― | ― | -19.35% | |
42 Neutral | kr118.69M | -1.34 | -294.38% | ― | 186.74% | 73.17% | |
41 Neutral | kr96.32M | -0.18 | ― | ― | 52.38% | 74.36% |
* Healthcare Sector Average
SE:ATORX
Alligator Bioscience AB
0.18
-1.56
-89.63%
SE:ALZ
Alzinova AB
0.59
-1.34
-69.43%
SE:NICA
Nanologica AB
0.36
-0.47
-56.40%
SE:MODTX
Modus Therapeutics Holding AB
0.34
-0.16
-32.67%
SE:ACTI
Active Biotech AB
0.06
<0.01
8.93%
SE:NXTCL
NextCell Pharma AB
1.38
0.44
46.75%
Alligator Bioscience AB Corporate Events
Alligator Bioscience Explores Phase 3 Path for Mitazalimab in Pancreatic Cancer via Unicancer Pact
Apr 10, 2026
Alligator Bioscience has signed a letter of intent with French non-profit cancer research network Unicancer to explore a potential global investigator-sponsored Phase 3 trial of its CD40-targeting antibody mitazalimab in first-line metastatic panc...
Alligator Bioscience Updates Share Count After Warrant Exercise
Mar 31, 2026
Alligator Bioscience AB has increased its total number of shares and votes during March 2026 following the exercise of warrants in series TO 14 that were issued as part of a rights issue of units carried out in late 2025. As of 31 March 2026, the ...
Alligator Bioscience Calls AGM and Proposes No Dividend Amid Continued Losses
Mar 30, 2026
Alligator Bioscience AB has called its annual general meeting for 6 May 2026 at Medicon Village in Lund, Sweden, setting out the formal requirements for shareholder participation, including share registration and notice procedures. The agenda cove...
Alligator Bioscience Adds Seasoned Pharma Leaders to Proposed Board Slate
Mar 27, 2026
Alligator Bioscience’s nomination committee has proposed the re-election of Hans-Peter Ostler and Denise Goode as ordinary board members and the election of industry veterans Anna Törner and Jörg Möller as new ordinary board m...
Alligator Bioscience Publishes 2025 Annual Report Highlighting Cancer Immunotherapy Progress
Mar 26, 2026
Alligator Bioscience AB has released its annual report for 2025, outlining a year centered on advancing its portfolio of tumor-targeted immunotherapies for cancer treatment. The report details significant events, financial performance and strategi...
Alligator Bioscience Raises SEK 19 Million Through TO 14 Warrant Exercise
Mar 20, 2026
Alligator Bioscience AB has completed the exercise period for its TO 14 warrants, issued in connection with a 2025 rights issue, resulting in 93,589,862 warrants being converted into the same number of new ordinary shares at SEK 0.20 each, an exer...
Alligator Bioscience to Present New Mitazalimab Pancreatic Cancer Data at AACR 2026
Mar 18, 2026
Alligator Bioscience announced that new data from an investigator-initiated Phase 1 trial of intratumoral mitazalimab in combination with irreversible electroporation in locally advanced pancreatic ductal adenocarcinoma will be presented at the AA...
Alligator Bioscience Executives Back TO 14 Warrant Exercise, Potentially Raising SEK 49 Million
Mar 16, 2026
Alligator Bioscience’s CEO Søren Bregenholt and CFO Johan Giléus plan to subscribe for their full pro rata portions in the company’s ongoing TO 14 warrant exercise, signaling management’s confidence in the business and ...
Alligator Bioscience Wins U.S. Patent for Bispecific Antibody Platform
Mar 10, 2026
Alligator Bioscience has secured a U.S. patent covering its proprietary tetravalent bispecific antibody format, which enables dual antigen binding and supports stable, efficient assembly of complex antibody constructs. The protected architecture i...
Alligator Bioscience Sees Revenue Upside as Henlius Advances HLX22 into Phase 2/3 Breast Cancer Trial
Mar 2, 2026
Alligator Bioscience has highlighted progress at partner Shanghai Henlius Biotech, which has dosed the first patient in a Phase 2/3 trial of HLX22 combined with antibody-drug conjugate HLX87 in first-line HER2-positive recurrent or metastatic brea...
Alligator Bioscience Sets TO 14 Warrant Exercise Price at SEK 0.20
Feb 27, 2026
Alligator Bioscience has set the exercise price for its TO 14 warrants at SEK 0.20 per share, following a rights issue and directed issue that together created 245,351,657 outstanding warrants. The exercise period runs from 5 to 19 March 2026, wit...
Alligator Bioscience Bolsters Finances and Pipeline as Mitazalimab Advances
Feb 12, 2026
Alligator Bioscience reported its 2025 year-end results highlighting a rights issue that raised approximately SEK 91 million before costs to bolster liquidity and support further development of lead cancer drug candidate mitazalimab. The financing...
Alligator Bioscience Sets Date for 2025 Earnings Report and Investor Call
Feb 5, 2026
Alligator Bioscience will publish its full-year 2025 report on 12 February 2026 and on the same day host an English-language webinar and conference call for investors, analysts and media, led by CEO Søren Bregenholt and CFO Johan Giléus....
Alligator Bioscience Expands Share Capital to Over 534 Million Shares
Jan 30, 2026
Alligator Bioscience AB has increased its total number of outstanding shares and votes to 534,516,986 ordinary shares as of 30 January 2026, following a rights issue of units approved in late 2025 and a subsequent directed issue of units to guaran...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.